

Seok Jin Nam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7694756/publications.pdf>

Version: 2024-02-01

201
papers

3,834
citations

172457

29
h-index

223800

46
g-index

213
all docs

213
docs citations

213
times ranked

6441
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 443-452.	2.5	145
2	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. <i>Nature Communications</i> , 2018, 9, 1725.	12.8	122
3	Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. <i>BMC Cancer</i> , 2015, 15, 138.	2.6	119
4	Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1495.	7.1	112
5	Development of microRNA-145 for therapeutic application in breast cancer. <i>Journal of Controlled Release</i> , 2011, 155, 427-434.	9.9	109
6	Basic Facts of Breast Cancer in Korea in 2014: The 10-Year Overall Survival Progress. <i>Journal of Breast Cancer</i> , 2017, 20, 1.	1.9	98
7	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 255-266.	2.5	96
8	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. <i>Nature Communications</i> , 2020, 11, 6175.	12.8	92
9	Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. <i>Oncotarget</i> , 2015, 6, 43731-43742.	1.8	63
10	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1338-1350.	3.0	56
11	Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. <i>Phytomedicine</i> , 2018, 50, 43-49.	5.3	56
12	Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 434-443.	1.6	52
13	MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 41-56.	2.5	51
14	Berberine Suppresses Cell Motility Through Downregulation of TGF- β 21 in Triple Negative Breast Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 795-807.	1.6	47
15	Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients. <i>Nutrients</i> , 2019, 11, 37.	4.1	46
16	The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imaging. <i>Journal of Surgical Oncology</i> , 2010, 102, 392-397.	1.7	44
17	The relationship between nuclear factor (NF)- κ B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. <i>Scientific Reports</i> , 2016, 6, 31804.	3.3	44
18	Immune gene expression profiling reveals heterogeneity in luminal breast tumors. <i>Breast Cancer Research</i> , 2019, 21, 147.	5.0	43

#	ARTICLE	IF	CITATIONS
19	Zerumbone suppresses the motility and tumorigenicity of triple negative breast cancer cells via the inhibition of TGF- β 1 signaling pathway. <i>Oncotarget</i> , 2016, 7, 1544-1558.	1.8	43
20	Elevated TGF- β 1 and - β 2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells. <i>Cytokine</i> , 2015, 75, 151-158.	3.2	40
21	The Basic Facts of Korean Breast Cancer in 2012: Results from a Nationwide Survey and Breast Cancer Registry Database. <i>Journal of Breast Cancer</i> , 2015, 18, 103.	1.9	39
22	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. <i>BMC Cancer</i> , 2016, 16, 138.	2.6	39
23	Elevated IL-1 β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone. <i>Chemico-Biological Interactions</i> , 2016, 258, 126-133.	4.0	38
24	Comparison of the Characteristics of Medullary Breast Carcinoma and Invasive Ductal Carcinoma. <i>Journal of Breast Cancer</i> , 2013, 16, 417.	1.9	37
25	Preoperative Axillary US in Early-Stage Breast Cancer: Potential to Prevent Unnecessary Axillary Lymph Node Dissection. <i>Radiology</i> , 2018, 288, 55-63.	7.3	37
26	Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 475-489.	2.5	33
27	Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. <i>Oncotarget</i> , 2017, 8, 50570-50581.	1.8	33
28	Role of secreted type I collagen derived from stromal cells in two breast cancer cell lines. <i>Oncology Letters</i> , 2014, 8, 507-512.	1.8	32
29	Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 54.	5.0	32
30	Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry. <i>Journal of Breast Cancer</i> , 2017, 20, 297.	1.9	31
31	Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype. <i>Oncology</i> , 2018, 95, 163-169.	1.9	31
32	MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells. <i>Tumor Biology</i> , 2016, 37, 4991-4999.	1.8	30
33	Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF- β 2 expression. <i>Tumor Biology</i> , 2016, 37, 11397-11407.	1.8	28
34	Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 95-102.	2.5	28
35	Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. <i>Oncotarget</i> , 2017, 8, 61538-61550.	1.8	28
36	Prognostic Validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean Patients with Breast Cancer. <i>Journal of Breast Cancer</i> , 2018, 21, 173.	1.9	28

#	ARTICLE	IF	CITATIONS
37	Efficacy of health coaching and a web-based program on physical activity, weight, and distress management among cancer survivors: A multi-centered randomised controlled trial. <i>Psycho-Oncology</i> , 2020, 29, 1105-1114.	2.3	28
38	Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal Carcinoma <i>In Situ</i> . <i>Journal of Breast Cancer</i> , 2013, 16, 404.	1.9	27
39	Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. <i>Oncology Reports</i> , 2014, 32, 2230-2236.	2.6	27
40	Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. <i>PLoS ONE</i> , 2015, 10, e0124658.	2.5	27
41	Who are happy survivors? Physical, psychosocial, and spiritual factors associated with happiness of breast cancer survivors during the transition from cancer patient to survivor. <i>Psycho-Oncology</i> , 2017, 26, 1922-1928.	2.3	27
42	Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 737-745.	2.5	27
43	Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 189-199.	2.5	27
44	Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence. <i>JAMA Surgery</i> , 2020, 155, 1132.	4.3	27
45	A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2 ⁻ early breast cancer. <i>Scientific Reports</i> , 2017, 7, 45554.	3.3	26
46	Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast. <i>Translational Oncology</i> , 2018, 11, 18-23.	3.7	26
47	EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2019, 53, 805-819.	1.6	26
48	Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells. <i>Oncology Reports</i> , 2014, 32, 2666-2672.	2.6	25
49	Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 591-596.	2.5	25
50	Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. <i>Oncotarget</i> , 2017, 8, 100296-100311.	1.8	25
51	Patient-reported assessment of self-management strategies of health in cancer patients: development and validation of the Smart Management Strategy for Health Assessment Tool (SAT). <i>Psycho-Oncology</i> , 2015, 24, 1723-1730.	2.3	24
52	Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 495-504.	2.8	24
53	Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study. <i>Clinical Breast Cancer</i> , 2017, 17, 204-210.	2.4	24
54	Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. <i>Clinical Breast Cancer</i> , 2018, 18, e1141-e1147.	2.4	24

#	ARTICLE	IF	CITATIONS
55	Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis. <i>Journal of Breast Cancer</i> , 2015, 18, 22.	1.9	23
56	Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. <i>Breast</i> , 2015, 24, 213-217.	2.2	23
57	Surgery of primary tumour has survival benefit in metastatic breast cancer with single organ metastasis, especially bone. <i>ANZ Journal of Surgery</i> , 2015, 85, 240-244.	0.7	23
58	Impact of Serum Lipid on Breast Cancer Recurrence. <i>Journal of Clinical Medicine</i> , 2020, 9, 2846.	2.4	23
59	Invasive Paget disease of the breast: 20 years of experience at a single institution. <i>Human Pathology</i> , 2014, 45, 2480-2487.	2.0	22
60	Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 437-444.	2.5	22
61	Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 169.	1.0	22
62	Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. <i>Oncology Reports</i> , 2015, 34, 1613-1619.	2.6	21
63	Feasibility of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Breast Cancer Patients with Tumor-Nipple Distance Less Than 2.0 cm. <i>World Journal of Surgery</i> , 2016, 40, 2028-2035.	1.6	21
64	Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 69-78.	1.1	21
65	Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. <i>Radiation Oncology Journal</i> , 2013, 31, 222.	1.5	21
66	The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women. <i>Annals of Surgical Oncology</i> , 2015, 22, 3481-3488.	1.5	20
67	Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 833-842.	2.5	20
68	The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. <i>BMC Cancer</i> , 2016, 16, 319.	2.6	19
69	Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis. <i>Journal of Breast Cancer</i> , 2018, 21, 433.	1.9	19
70	Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells. <i>Journal of Breast Cancer</i> , 2018, 21, 21.	1.9	19
71	Association between cancer stigma and job loss among cancer survivors. <i>Psycho-Oncology</i> , 2021, 30, 1347-1355.	2.3	19
72	Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. <i>Journal of Breast Cancer</i> , 2021, 24, 75.	1.9	19

#	ARTICLE	IF	CITATIONS
73	Distress and body image due to altered appearance in posttreatment and active treatment of breast cancer patients and in general population controls. <i>Palliative and Supportive Care</i> , 2018, 16, 137-145.	1.0	19
74	Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 95-102.	1.1	19
75	Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells. <i>Annals of Surgical Treatment and Research</i> , 2014, 87, 167.	1.0	18
76	Predictive Factors for Nonsentinel Lymph Node Metastasis in Patients With Positive Sentinel Lymph Nodes After Neoadjuvant Chemotherapy: Nomogram for Predicting Nonsentinel Lymph Node Metastasis. <i>Clinical Breast Cancer</i> , 2017, 17, 550-558.	2.4	18
77	Risk Factors Affecting Breast Cancer-related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane. <i>Clinical Breast Cancer</i> , 2018, 18, e49-e54.	2.4	18
78	Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment. <i>PLoS ONE</i> , 2019, 14, e0212309.	2.5	18
79	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 325-334.	2.5	18
80	Oncologic Outcomes of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Patients with Tumor-Nipple Distance Less than 2.0 cm. <i>Journal of Breast Cancer</i> , 2019, 22, 613.	1.9	18
81	Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype. <i>Korean Journal of Radiology</i> , 2015, 16, 986.	3.4	17
82	Lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma, is it really necessary? A randomized, controlled study. <i>Surgery</i> , 2015, 157, 518-525.	1.9	17
83	A predictive model for high/low risk group according to onco-type DX recurrence score using machine learning. <i>European Journal of Surgical Oncology</i> , 2019, 45, 134-140.	1.0	17
84	Celastrol attenuates the inflammatory response by inhibiting IL-1 β expression in triple-negative breast cancer cells. <i>Oncology Reports</i> , 2021, 45, .	2.6	17
85	Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants. <i>Genetics in Medicine</i> , 2016, 18, 1250-1257.	2.4	16
86	Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from "unknown significance" to "Likely pathogenic" based on clinical evidence in Korea. <i>Breast</i> , 2017, 33, 109-116.	2.2	16
87	Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study. <i>Journal of Breast Cancer</i> , 2017, 20, 74.	1.9	15
88	Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 385-395.	2.5	15
89	STC-1 expression is upregulated through an Akt/NF- κ B-dependent pathway in triple-negative breast cancer cells. <i>Oncology Reports</i> , 2016, 36, 1717-1722.	2.6	14
90	Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, e19-e29.	2.4	14

#	ARTICLE	IF	CITATIONS
91	<i>PIK3CA</i> Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. <i>Journal of Breast Cancer</i> , 2018, 21, 382.	1.9	14
92	Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry. <i>Frontiers in Oncology</i> , 2021, 11, 596364.	2.8	14
93	Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 502-502.	1.6	14
94	Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 86423-86434.	1.8	14
95	Breast Cancer Screening Knowledge and Perceived Health Beliefs among Immigrant Women in Korea. <i>Journal of Breast Cancer</i> , 2014, 17, 279.	1.9	13
96	Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery. <i>Journal of Breast Cancer</i> , 2015, 18, 386.	1.9	13
97	Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	13
98	The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 1.	1.5	13
99	Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 203-215.	2.5	13
100	Adherence to the American Cancer Society Guidelines for Cancer Survivors and Health-Related Quality of Life among Breast Cancer Survivors. <i>Nutrients</i> , 2019, 11, 2924.	4.1	13
101	Ovarian function preservation with GnRH agonist in young breast cancer patients: Does it impede the effect of adjuvant chemotherapy?. <i>Breast</i> , 2014, 23, 670-675.	2.2	12
102	Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study. <i>Journal of Breast Cancer</i> , 2015, 18, 8.	1.9	12
103	Comparison of Clinicopathological Features and Treatment Results between Invasive Lobular Carcinoma and Ductal Carcinoma of the Breast. <i>Journal of Breast Cancer</i> , 2015, 18, 285.	1.9	12
104	Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 329-336.	1.1	12
105	Development of a Nomogram to Predict N2 or N3 Stage in T1-2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy. <i>Journal of Breast Cancer</i> , 2017, 20, 270.	1.9	12
106	BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. <i>PLoS ONE</i> , 2018, 13, e0207155.	2.5	12
107	Response of Triple-negative Breast Cancer Liver Metastasis to Oral Recombinant Methioninase in a Patient-derived Orthotopic Xenograft (PDOX) Model. <i>In Vivo</i> , 2020, 34, 3163-3169.	1.3	12
108	Oral Methioninase Inhibits Recurrence in a PDOX Mouse Model of Aggressive Triple-negative Breast Cancer. <i>In Vivo</i> , 2020, 34, 2281-2286.	1.3	12

#	ARTICLE	IF	CITATIONS
109	Biopsychosocial Predictors of the Quality of Life in Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2010, 13, 219.	1.9	11
110	Initial Experience with a Wireless Ultrasound-Guided Vacuum-Assisted Breast Biopsy Device. <i>PLoS ONE</i> , 2015, 10, e0144046.	2.5	11
111	Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. <i>Journal of Breast Cancer</i> , 2016, 19, 169.	1.9	11
112	Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 5260.	3.7	11
113	Excision alone for small size ductal carcinoma in situ of the breast. <i>Breast</i> , 2014, 23, 586-590.	2.2	10
114	Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. <i>Cancer Research and Treatment</i> , 2016, 48, 1382-1388.	3.0	10
115	Only estrogen receptor α -positive is not enough to predict the prognosis of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 627-636.	2.5	10
116	Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy. <i>Journal of Breast Cancer</i> , 2018, 21, 91.	1.9	10
117	Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 747-757.	2.5	10
118	Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 653-663.	2.5	10
119	Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. <i>Clinical Breast Cancer</i> , 2015, 15, 512-518.	2.4	9
120	Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer. <i>World Journal of Surgery</i> , 2018, 42, 1384-1390.	1.6	9
121	Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	9
122	WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells. <i>Cytokine</i> , 2020, 135, 155213.	3.2	9
123	Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors. <i>Cancer Research and Treatment</i> , 2022, 54, 834-841.	3.0	9
124	Genetic anticipation of familial breast cancer with or without BRCA mutation in the Korean population. <i>Cancer Genetics</i> , 2014, 207, 160-163.	0.4	8
125	Protein kinase C δ downregulates estrogen receptor α by suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells. <i>Oncology Reports</i> , 2014, 31, 1423-1428.	2.6	8
126	Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society. <i>Medical Oncology</i> , 2017, 34, 118.	2.5	8

#	ARTICLE	IF	CITATIONS
127	Development and validation of the smart management strategy for health assessment tool-short form (SAT-SF) in cancer survivors. <i>Quality of Life Research</i> , 2018, 27, 347-354.	3.1	8
128	Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2018, 34, 663-672.	1.9	8
129	Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?. <i>Journal of Breast Cancer</i> , 2018, 21, 206.	1.9	8
130	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1315-1325.	3.4	8
131	Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?. <i>BMC Cancer</i> , 2021, 21, 88.	2.6	8
132	Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 955-961.	3.0	8
133	Surgical impact on anxiety of patients with breast cancer: 12-month follow-up prospective longitudinal study. <i>Annals of Surgical Treatment and Research</i> , 2020, 98, 215.	1.0	8
134	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. <i>Cancer Research and Treatment</i> , 2022, , .	3.0	8
135	Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. <i>Oncotarget</i> , 2015, 6, 24499-24510.	1.8	7
136	Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0165814.	2.5	7
137	MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells. <i>Oncology Reports</i> , 2016, 35, 2398-2404.	2.6	7
138	A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors. <i>BMC Cancer</i> , 2018, 18, 45.	2.6	7
139	TP53 upregulates β -smooth muscle actin expression in tamoxifen-resistant breast cancer cells. <i>Oncology Reports</i> , 2019, 41, 1075-1082.	2.6	7
140	Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 232-239.	1.0	7
141	Entelon® (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells. <i>Molecules</i> , 2021, 26, 3644.	3.8	7
142	Primary Follicular Lymphoma in a Male Breast: A Case Report. <i>Cancer Research and Treatment</i> , 2014, 46, 104-107.	3.0	7
143	Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. <i>Clinical Breast Cancer</i> , 2015, 15, e197-e204.	2.4	6
144	Incidental Findings on Simulation CT Images for Adjuvant Radiotherapy in Breast Cancer Patients. <i>Technology in Cancer Research and Treatment</i> , 2015, 14, 525-529.	1.9	6

#	ARTICLE	IF	CITATIONS
145	Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. PLoS ONE, 2016, 11, e0163254.	2.5	6
146	Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society. Breast Cancer Research and Treatment, 2016, 159, 489-498.	2.5	6
147	Fertility Rates in Young Korean Breast Cancer Patients Treated with Gonadotropin-Releasing Hormone and Chemotherapy. Journal of Breast Cancer, 2017, 20, 91.	1.9	6
148	A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model. Anticancer Research, 2020, 40, 2481-2485.	1.1	6
149	Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].. Journal of Clinical Oncology, 2019, 37, 576-576.	1.6	6
150	Polyostotic Fibrous Dysplasia Mimicking Multiple Bone Metastases in a Patient with Ductal Carcinoma In Situ. Journal of Breast Cancer, 2014, 17, 83.	1.9	5
151	Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy. Journal of Breast Cancer, 2014, 17, 244.	1.9	5
152	Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer. Journal of Breast Cancer, 2015, 18, 50.	1.9	5
153	Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women. BMC Cancer, 2017, 17, 821.	2.6	5
154	The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer. PLoS ONE, 2018, 13, e0197523.	2.5	5
155	Distribution of tumor subtypes in bilateral breast cancer: Comparison between synchronous and metachronous cancer. Asia-Pacific Journal of Clinical Oncology, 2020, , .	1.1	5
156	The efficacy and safety of indocyanine green-hyaluronic acid mixture (LuminoMark [®] , [®]) for localization in patients with non-palpable breast lesions: a multi-center open-label parallel phase-2 clinical trial. BMC Surgery, 2021, 21, 134.	1.3	5
157	Is the intraoperative frozen section analysis of sentinel lymph nodes necessary in clinically negative node breast cancer?. Annals of Surgical Treatment and Research, 2020, 99, 251.	1.0	5
158	The Protective Effect of Parity in Hormone Receptor-Positive, Ki-67 Expressing Breast Cancer. World Journal of Surgery, 2014, 38, 1065-1069.	1.6	4
159	Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype. Breast, 2016, 30, 111-117.	2.2	4
160	Verification of a Western Nomogram for Predicting Oncotype DX [®] , [®] Recurrence Scores in Korean Patients with Breast Cancer. Journal of Breast Cancer, 2018, 21, 222.	1.9	4
161	Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea. Frontiers in Oncology, 2021, 11, 691277.	2.8	4
162	Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer. Cancer Research and Treatment, 2015, 47, 765-773.	3.0	4

#	ARTICLE	IF	CITATIONS
163	Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society. <i>Journal of Breast Cancer</i> , 2022, 25, 94.	1.9	4
164	One-step Nucleic Acid Amplification (OSNA): Intraoperative Rapid Molecular Diagnostic Method for the Detection of Sentinel Lymph Node Metastases in Breast Cancer Patients in Korean Cohort. <i>Journal of Breast Cancer</i> , 2010, 13, 366.	1.9	3
165	Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 273-282.	2.5	3
166	Effect of Poloxamer-Based Thermo-Sensitive Sol-Gel Agent on Upper Limb Dysfunction after Axillary Lymph Node Dissection: A Double-Blind Randomized Clinical Trial. <i>Journal of Breast Cancer</i> , 2021, 24, 367.	1.9	3
167	Effect of mind and body education on quality of life among young breast cancer patients: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2022, 30, 721-729.	2.2	3
168	Scanxiety and quality of life among breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20569-e20569.	1.6	3
169	Comparison of prognosis and specific features according to tumor size in small-sized breast cancer with extensive lymph node involvement.. <i>Journal of Clinical Oncology</i> , 2015, 33, 81-81.	1.6	3
170	Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2020, 23, 259.	1.9	3
171	Patterns of Axillary Lymph Node Metastasis in Breast Cancer: A Prospective Single-Center Study. <i>Journal of Breast Cancer</i> , 2018, 21, 447.	1.9	2
172	Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment. <i>Journal of Breast Cancer</i> , 2018, 21, 182.	1.9	2
173	Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 104-113.	1.3	2
174	Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006). <i>Journal of Breast Cancer</i> , 2021, 24, 164.	1.9	2
175	Changes in Korean National Healthcare Insurance Policy and Breast Cancer Surgery Trend in Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e194.	2.5	2
176	Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2- Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 588728.	2.8	2
177	Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 741120.	2.8	2
178	Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2022, 54, 827-833.	3.0	2
179	A Comparison of Clinical Outcomes for Breast-conserving Treatment and Mastectomy for Early Breast Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2008, 26, 10.	0.1	2
180	Histologic analysis according to HER2 gene status in HER2 -invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 749-758.	2.8	2

#	ARTICLE	IF	CITATIONS
181	Limited Supraclavicular Radiation Field in Breast Cancer With ≥ 10 Positive Axillary Lymph Nodes. <i>Clinical Breast Cancer</i> , 2016, 16, e15-e21.	2.4	1
182	Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy. <i>Clinical Breast Cancer</i> , 2018, 18, e1165-e1172.	2.4	1
183	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 14747.	3.3	1
184	Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 608207.	2.8	1
185	A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer (KBCSG 012).. <i>Journal of Clinical Oncology</i> , 2017, 35, 517-517.	1.6	1
186	Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 101-112.	2.5	1
187	A Case of Sliding Hiatal Hernia associated with Bochdalek Hernia Repair. <i>Journal of the Korean Association of Pediatric Surgeons</i> , 1996, 2, 129.	0.1	0
188	Dietary Intake and Plasma Levels of Isoflavones Among Breast Cancer Survivors. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa061_118.	0.3	0
189	Aberrant Lymphatic Drainage in the Contralateral Axilla in Patients with Isolated Ipsilateral Breast Tumor Recurrence. <i>Journal of Clinical Medicine</i> , 2020, 9, 1192.	2.4	0
190	Abstract PS10-38: Real World Evidence (RWE) of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2 positive early or locally advanced breast cancer treated Single institutional experience. , 2021, , .		0
191	Is Sentinel Lymph Node Biopsy for Breast Cancer with Cytology-Proven Axillary Metastasis Safe? A Prospective Single-Arm Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4754.	2.4	0
192	The Role of Needle Localization Breast Biopsy for the Diagnosis of Nonpalpable Breast Cancer. <i>Journal of Korean Breast Cancer Society</i> , 2000, 3, 42.	0.1	0
193	Clinical Analysis of Adrenal Tumors. <i>The Korean Journal of Endocrine Surgery</i> , 2003, 3, 147.	0.1	0
194	Commentary on "The Number of Removed Lymph Nodes for an Acceptable False Negative Rate in Sentinel Node Biopsy for Breast Cancer". <i>Journal of Breast Cancer</i> , 2009, 12, 227.	1.9	0
195	Characteristics of medullary breast carcinoma compared with invasive ductal carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 20-20.	1.6	0
196	Surgical Outcomes of Bilateral Adrenalectomy. <i>The Korean Journal of Endocrine Surgery</i> , 2013, 13, 234.	0.1	0
197	Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 195-195.	1.6	0
198	Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytology proven axillary node-positive breast cancer at diagnosis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12640-e12640.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with breast cancer. Cancer Research, 2022, 82, P1-08-07-P1-08-07.	0.9	0
200	Abstract OT1-04-02: The NAUTILUS trial (No Axillary sUrgical Treatment In clinically Lymph node) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 (NCT04303715). Cancer Research, 2022, 82, OT1-04-02-OT1-04-02.	0.9	0
201	Abstract P3-13-08: Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples. Cancer Research, 2022, 82, P3-13-08-P3-13-08.	0.9	0